Su Jian, Leng Qixin, Lin Yanli, Ma Jie, Jiang Fangran, Lee Cheng-Ju, Fang HongBin, Jiang Feng
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Biomark Cancer. 2018 Feb 13;10:1179299X18759297. doi: 10.1177/1179299X18759297. eCollection 2018.
We have demonstrated that assessments of microRNA (miRNA) expressions in circulating peripheral blood mononucleated cell (PBMC) and sputum specimens, respectively, may help diagnose lung cancer. To assess the individual and combined analysis of the miRNAs across the different body fluids for lung cancer early detection, we analyse a panel of 3 sputum miRNAs (miRs-21, 31, and 210) and a panel of 2 PBMC miRNAs (miRs-19b-3p and 29b-3p) in a discovery cohort of 68 patients with lung cancer and 66 cancer-free smokers. We find that integrating 2 sputum miRNAs (miRs-31 and 210) and 1 PBMC miRNA (miR-19b-3p) has higher sensitivity (86.8%) and specificity (92.4%) compared with the individual panels. The synergistic value of the integrated panel of 3 biomarkers is confirmed in a validation cohort, independent of stage and histological type of lung cancer, and patients' age, sex, and ethnicity. Integrating circulating immunological and sputum biomarkers could improve the early detection of lung cancer.
我们已经证明，分别评估循环外周血单核细胞（PBMC）和痰液样本中的微小RNA（miRNA）表达可能有助于诊断肺癌。为了评估跨不同体液的miRNA用于肺癌早期检测的个体分析和联合分析，我们在一个由68例肺癌患者和66例无癌吸烟者组成的发现队列中分析了一组3种痰液miRNA（miR-21、31和210）和一组2种PBMC miRNA（miR-19b-3p和29b-3p）。我们发现，与单个检测组相比，整合2种痰液miRNA（miR-31和210）和1种PBMC miRNA（miR-19b-3p）具有更高的敏感性（86.8%）和特异性（92.4%）。3种生物标志物联合检测组的协同价值在一个验证队列中得到证实，该队列独立于肺癌的分期和组织学类型以及患者的年龄、性别和种族。整合循环免疫和痰液生物标志物可以改善肺癌的早期检测。
